ストックスクリーナーアプリを入手
6.34
6.73%
0.40
前日終値:
$5.94
開ける：
$5.96
24時間の取引高:
3.12M
Relative Volume:
14.80
時価総額：
$318.43M
収益：
-
当期純損益:
$-76.41M
株価収益率:
-3.3021
EPS:
-1.92
ネットキャッシュフロー:
$-64.56M
1週間 パフォーマンス:
-15.47%
1か月 パフォーマンス:
-13.98%
6か月 パフォーマンス:
-29.79%
1年 パフォーマンス:
-19.24%
1日の値動き範囲:
$5.85
$6.36
1週間の範囲:
$5.77
$7.73
52週間の値動き範囲:
$5.77
$12.38
Aura Biosciences Inc Stock (AURA) Company Profile
AURA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
6.34 | 318.43M | 0 | -76.41M | -64.56M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-25 | 開始されました | H.C. Wainwright | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-04-17 | 再開されました | BTIG Research | Buy |
| 2022-07-19 | 開始されました | JMP Securities | Mkt Outperform |
Aura Biosciences Inc (AURA) 最新ニュース
Q1 Earnings Estimate for AURA Issued By HC Wainwright - Defense World
Aura Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Institutional investors may adopt severe steps after Aura Biosciences, Inc.'s (NASDAQ:AURA) latest 20% drop adds to a year losses - Simply Wall St
Aura Biosciences Inc: Promising Clinical Progress and Financial Stability Justify Buy Rating - TipRanks
What is HC Wainwright’s Forecast for AURA Q3 Earnings? - Defense World
Aura Biosciences Stock (AURA) Continues to Slide Despite Promising Clinical Progress - Markets Insider
Aura Biosciences price target lowered to $19 from $21 at Citizens JMP - TipRanks
Character Biosciences gains $93m for precision eye disease therapies - Pharmaceutical Technology
Bel-sar shows promising safety, efficacy in NMIBC - Urology Times
Aura Biosciences stock target cut to $19 by JMP Securities - Investing.com UK
Aura Biosciences Reports Progress in Cancer Trials - TipRanks
Aura Biosciences Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
Aura Biosciences stock target raised to $25 by H.C. Wainwright - Investing.com UK
Promising Clinical Data and Abscopal Effect Drive Buy Rating for Aura Biosciences Inc. - TipRanks
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - GlobeNewswire
Aura's Cancer Drug Delivers Complete Responses as $151M Cash Runway Extends to 2026 - StockTitan
Promising Phase 1 Results for Aura Biosciences’ Bel-sar in Bladder Cancer Boost Buy Rating - TipRanks
Aura reports promising bladder cancer trial results By Investing.com - Investing.com South Africa
Aura Biosciences stock hits 52-week low at $6.58 amid market shifts - Investing.com Australia
Buy Recommendation for Aura Biosciences: Promising Phase 1 Trial Results and Dual Mechanism of Action in Bladder Cancer Treatment - TipRanks
Aura Biosciences stock hits 52-week low at $6.58 amid market shifts By Investing.com - Investing.com South Africa
Buy Rating for Aura Biosciences Inc. Driven by Promising Phase 1 Trial Results and Future Revenue Potential - TipRanks
Aura Biosciences Reports 'Robust' Anti-Tumor Immune Response From Phase 1 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer - Marketscreener.com
Aura reports promising bladder cancer trial results - Investing.com India
Aura Biosciences announces data from Phase 1 trial of bel-sar in NMIBC - TipRanks
Positive Data from Phase 1 Trial of Bel-sar in Patients - GlobeNewswire
Breakthrough: New Bladder Cancer Drug Achieves 80% Response Rate in Clinical Trial - StockTitan
With 48% stake, Aura Biosciences, Inc. (NASDAQ:AURA) seems to have captured institutional investors' interest - Yahoo Finance
Aura Biosciences, Inc. (NASDAQ:AURA) Sees Large Decrease in Short Interest - Defense World
Analysts Set Groupon, Inc. (NASDAQ:GRPN) PT at $17.33 - Defense World
Innovative Industrial Properties, Inc. (NYSE:IIPR) Receives $102.00 Average Target Price from Analysts - Defense World
Aura Biosciences, Inc. (NASDAQ:AURA) Receives $23.00 Consensus Target Price from Brokerages - Defense World
Learn to Evaluate (AURA) using the Charts - Stock Traders Daily
Aura Biosciences (AURA) to Release Quarterly Earnings on Wednesday - Defense World
Teladoc (TDOC) Harnesses AI for Diabetes Care, Stock Rises 6.7% - MSN
TCR Therapy Clinical Trial Pipeline Accelerates as 80+ - GlobeNewswire
Tarsus Pharmaceuticals (NASDAQ:TARS) & Aura Biosciences (NASDAQ:AURA) Critical Survey - Defense World
H.C. Wainwright maintains $22 target on Aura Biosciences stock By Investing.com - Investing.com UK
Buy Rating for Aura Biosciences Driven by Promising Bel-sar Developments and Market Potential - TipRanks
Promising Developments in Aura Biosciences Inc’s Clinical Trials Lead to Buy Rating - TipRanks
Aura Biosciences to present new bladder cancer study data - Investing.com
Aura Biosciences to Present Phase 1 Data on Bel-sar and Host Virtual Urologic Oncology Investor Event at 40th Annual EAU Congress - Nasdaq
Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress - GlobeNewswire
Will Aura's Bladder Cancer Treatment Change Patient Outcomes? New Data Coming in 2025 - StockTitan
How to Take Advantage of moves in (AURA) - Stock Traders Daily
Syndax Announces Participation in March Investor Conferences - The Manila Times
Aura Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire
How Will Aura Biosciences Address Investors at Two Major Healthcare Conferences Next Month? - StockTitan
Advancing Immunotherapy With FDA Approval Of ANKTIVA For BCG-Unresponsive Bladder Cancer: Key Trend Transfo... - WhaTech
Brokerages Set Aura Biosciences, Inc. (NASDAQ:AURA) Target Price at $23.00 - Defense World
Aura Biosciences CEO sells shares worth $156,795 - Investing.com India
Aura Biosciences Inc (AURA) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):